Ergothioneine-containing muscular atrophy suppressing composition and src tyrosine kinase inhibiting composition
Patent Information
- Application Number
- MYPI2025004914
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-16
- Filing Date
- 2024-02-13
- Publication Date
- 2024-08-16
AI Technical Summary
Aging populations often become bedridden or less active, leading to muscle atrophy, which is difficult to prevent with declining metabolic function, and existing solutions are inadequate for effectively suppressing muscle protein decomposition in elderly individuals.
A composition containing L-ergothioneine or its salt, which inhibits Src tyrosine kinase and suppresses muscle atrophy by acting on ATP-sensitive potassium channels, is used as an oral food or drink supplement to maintain muscle mass and strength.
The composition effectively suppresses muscle atrophy by inhibiting muscle protein decomposition and maintaining muscle mass and strength in elderly individuals, as demonstrated by reduced fat-free percentage and Src tyrosine kinase inhibition.
Smart Images

Figure PI2025004914_DRAWING_001
Abstract
Description
Ergothioneine-containing composition for inhibiting muscle atrophy and composition for inhibiting Src tyrosine kinase
[0001] The present invention relates to a composition for inhibiting muscle atrophy and a composition for inhibiting Src tyrosine kinase, each containing ergothioneine.
[0002] As the aging population increases worldwide, elderly people are becoming bedridden and their activity levels decrease, leading to muscle atrophy, which in turn leads to a vicious cycle of further decreased activity levels, further promoting muscle atrophy. While the only reliable way to increase muscle mass is through continuous muscle training, the elderly experience a decline in metabolic function, making it difficult to maintain muscle mass through training alone. Therefore, there is a strong demand for pharmaceuticals and foods that can prevent muscle atrophy.
[0003] Muscle balance is maintained by the muscle protein synthesis and degradation systems, and different factors are involved in each of these systems. Muscle protein synthesis requires materials such as amino acids and energy, and a diet suitable for muscle protein is required. However, elderly people have a reduced appetite compared to younger people. Therefore, inhibiting the muscle protein degradation system is important and thought to be highly effective in preventing muscle atrophy in the elderly.
[0004] The Src tyrosine kinase family is an important intracellular signaling protein involved in acute inflammatory responses, and its phosphorylation is one of the major factors that determine the expression and production of inflammatory mediators. Src tyrosine kinase is expressed in muscle, and its inhibition suppresses muscle cell degradation.
[0005] Ergothioneine is an amino acid found in mushrooms etc., and naturally exists in the L-form. Patent Document 1 discloses a composition containing ergothioneine that promotes muscle differentiation, and describes in the Examples that culturing C2C12 cells in a medium containing ergothioneine promoted the differentiation of C2C12 cells into muscle cells and increased the expression level of MyoD mRNA, which induces muscle differentiation.
[0006] International Publication No. 2020 / 004014
[0007] However, Patent Document 1 does not describe at all the effects on muscle atrophy or the inhibition of Src tyrosine kinase.
[0008] An object of the present invention is to provide a composition for inhibiting muscle atrophy and a composition for inhibiting Src tyrosine kinase.
[0009] As a result of intensive research conducted by the present inventors to solve the above problems, they found that L-ergothioneine or a salt thereof has the effect of suppressing muscle atrophy and inhibits Src tyrosine kinase.
[0010] That is, the present invention relates to the following compositions for inhibiting muscle atrophy, but is not limited thereto. [1] A composition for inhibiting muscle atrophy, comprising ergothioneine or a salt thereof as an active ingredient. [2] The composition according to [1] above, wherein the muscle atrophy is age-related muscle atrophy. [3] The composition according to [1] or [2] above, which inhibits muscle atrophy via an ATP-sensitive potassium channel. [4] A composition for inhibiting Src tyrosine kinase, comprising ergothioneine or a salt thereof as an active ingredient. [5] The composition according to any of [1] to [4] above, which is an oral composition. [6] The composition according to any of [1] to [5] above, which is a food or drink. [7] The composition according to any one of [1] to [6] above, which is labeled with at least one function selected from the group consisting of "inhibition of muscle loss," "muscle maintenance," "muscle improvement," "inhibition of muscle weakness," "muscle strength maintenance," "muscle strength improvement," "improvement of walking function," "maintenance of walking function," "improvement of motor function," "maintenance of motor function," "maintenance of muscles weakened by aging," "maintenance of muscle strength weakened by aging," and "maintenance of physical strength." [8] A method for inhibiting muscle atrophy, comprising administering ergothioneine or a salt thereof to a subject. [9] A method for inhibiting Src tyrosine kinase, comprising administering ergothioneine or a salt thereof to a subject.
[10] Use of ergothioneine or a salt thereof to inhibit muscle atrophy.
[11] Use of ergothioneine or a salt thereof to inhibit Src tyrosine kinase.
[0011] According to the present invention, a composition for suppressing muscle atrophy can be provided. Also, according to the present invention, a composition for inhibiting Src tyrosine kinase can be provided.
[0012] FIG. 1 is a graph showing the change in lean tissue percentage (Δ lean tissue percentage (%)) in the test food group and the control food group. FIG. 2 is a graph evaluating the inhibitory activity of L-ergothioneine against Src tyrosine kinase. FIG. 3 is a graph evaluating the inhibitory activity of L-ergothioneine against substrate binding to ATP-sensitive potassium channels.
[0013] The composition for inhibiting muscle atrophy of the present invention contains ergothioneine or a salt thereof as an active ingredient. Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acidic salt or a basic salt. Examples of acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.
[0014] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
[0015] L-ergothioneine or a salt thereof is a compound that is contained in natural products and foods and beverages and has been consumed as a dietary source. Therefore, from the viewpoint of safety, ergothioneine or a salt thereof is considered to pose few problems, even when taken over a long period of time. According to the present invention, a highly safe composition for inhibiting muscle atrophy can be provided.
[0016] Muscle atrophy is the loss of muscle mass. Muscle atrophy can be caused by a disease of the muscle itself (myogenic muscle atrophy) or by a disorder of the motor nerves that directly transmit motor commands to the muscle (neurogenic muscle atrophy). Even in the absence of such muscle or nerve disease, muscles will lose weight if not used, a condition known as disuse muscle atrophy. Furthermore, the amount of muscle in the entire body decreases with age (age-related muscle atrophy). In one embodiment, the composition of the present invention is preferably used to inhibit age-related muscle atrophy, and more preferably to prevent age-related muscle atrophy.
[0017] As shown in the examples below, intake of L-ergothioneine inhibited the decrease in lean body mass compared to when it was not taken. Lean body mass (LBM) is the weight obtained by subtracting the weight of fat from body weight, and is an index for determining the proportion of muscle. By examining the increase or decrease in lean body mass, the increase or decrease in muscle weight can be determined. Lean body mass is the ratio of lean body mass to total body weight. A decrease in lean body mass indicates a decrease in muscle mass. Therefore, inhibition of the decrease in lean body mass indicates inhibition of the decrease in muscle mass. Therefore, ergothioneine can be used as an active ingredient for inhibiting muscle atrophy.
[0018] Furthermore, as shown in the Examples below, L-ergothioneine inhibited Src tyrosine kinase. Furthermore, L-ergothioneine inhibited substrate binding to ATP-sensitive potassium (KATP) channels. Src tyrosine kinase is expressed in muscles, and its inhibition is known to suppress muscle cell degradation. Therefore, ergothioneine inhibits muscle cell degradation by inhibiting Src tyrosine kinase, thereby exhibiting muscle atrophy inhibitory effects. KATP channels are expressed in muscles and are known to be involved in regulating the muscle atrophy process. Therefore, ergothioneine is thought to have a muscle atrophy inhibitory effect via ATP-sensitive potassium channels.
[0019] The composition of the present invention is used to inhibit muscle atrophy. Inhibition of muscle atrophy includes preventing muscle atrophy, delaying the progression of muscle atrophy, preventing the progression of muscle atrophy, etc. Prevention of muscle atrophy includes preventing the onset, delaying the onset, reducing the incidence, reducing the risk of onset, etc. Inhibition of muscle atrophy can result in effects such as inhibiting the loss of muscle mass and maintaining muscle mass.
[0020] The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Specific examples of oral compositions include foods and beverages, oral pharmaceuticals, quasi-drugs, feed, etc., and are preferably foods and beverages or oral pharmaceuticals, more preferably foods and beverages. The composition of the present invention may be a material or preparation to be incorporated into foods and beverages, pharmaceuticals, quasi-drugs, feed, etc.
[0021] The compositions of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes, the latter being a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis.
[0022] The composition of the present invention may contain any additives and any components in addition to ergothioneine or a salt thereof, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc. When the composition of the present invention is an oral composition, additives that can generally be used in oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used.
[0023] When the composition of the present invention is used in the form of a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc., the method for producing the composition is not particularly limited, and the composition can be produced by a general method. The form of the oral composition of the present invention is not particularly limited, and the composition may be in the form of a solid (powder, granules, tablet, etc.), a liquid, a paste, etc.
[0024] For example, when the composition of the present invention is made into a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.
[0025] When the composition of the present invention is used as a pharmaceutical or quasi-drug, it can be formulated into various dosage forms by blending ergothioneine or a salt thereof with a pharmacologically acceptable carrier and, if necessary, additives. Such carriers, additives, etc. may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc. The pharmaceutical or quasi-drug may be administered orally or parenterally (transdermally, transmucosally, enterally, by injection, etc.). When the composition of the present invention is used as a pharmaceutical or quasi-drug, it is preferably an oral pharmaceutical or oral quasi-drug. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, etc. Dosage forms for parenteral administration include, for example, injections, drip infusions, ointments, lotions, patches, suppositories, nasal preparations, pulmonary preparations (inhalants), etc. The pharmaceutical product may be a pharmaceutical product for non-human animals.
[0026] When the composition of the present invention is used as a feed, ergothioneine or a salt thereof may be blended into the feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.
[0027] The subject to which the composition of the present invention is ingested or administered (which can also be referred to as the administration subject) is not particularly limited. It is preferably a human or a non-human mammal, more preferably a human. In one embodiment, the administration subject includes a subject who requires or desires the inhibition of muscle atrophy. Examples of such subjects include middle-aged and elderly people. In one embodiment, the composition of the present invention is suitably used as a composition for inhibiting muscle atrophy for middle-aged and elderly people. Middle-aged and elderly people include elderly people. Middle-aged and elderly people may be, for example, people aged 40 or older. Elderly people may be, for example, people aged 60 or older or 65 or older. The administration subject may be a healthy individual. The composition of the present invention can also be used in healthy individuals, for example, for the purpose of inhibiting muscle atrophy. In the present invention, a particularly preferred subject is a healthy individual aged 50 or older but younger than 65, and a most preferred subject is a healthy individual aged 50 or older but younger than 55.
[0028] The content of ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and preferably 90% by weight or less, more preferably 50% by weight or less. In one aspect, the content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is preferably 0.0001 to 90% by weight, more preferably 0.001 to 50% by weight. The content of ergothioneine or a salt thereof can be measured by high-performance liquid chromatography (HPLC).
[0029] In this specification, the expression "ergothioneine equivalent amount" or similar expressions means the amount of ergothioneine, and in the case of a salt of ergothioneine, means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
[0030] The composition of the present invention can be ingested or administered in a suitable manner depending on its form. In one embodiment, the composition of the present invention is preferably ingested orally (orally administered). The dosage (also referred to as intake amount) of the composition of the present invention is not particularly limited, and may be an amount that can achieve the effect of suppressing muscle atrophy, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc.
[0031] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the dosage is preferably 2 mg or more, more preferably 5 mg or more, even more preferably 7 mg or more, and preferably 50 mg or less, more preferably 25 mg or less, and even more preferably 20 mg or less per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). In one embodiment, the dosage of the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and even more preferably 7 to 20 mg per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). It is preferable that the above amount be ingested or administered once or more times a day, for example, once a day or in divided doses (e.g., 2 to 3 times a day). In one embodiment, the above amount of ergothioneine or a salt thereof is orally ingested or administered to a human. The above dosage may be per 60 kg of body weight. In one embodiment, the composition of the present invention can be used to ingest or administer the above-mentioned amount of ergothioneine or a salt thereof per 60 kg of body weight per day to a human.
[0032] The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and particularly preferably 7 to 20 mg, of ergothioneine per daily intake for an adult.
[0033] The composition of the present invention may be labeled with, for example, a function of inhibiting muscle atrophy, or a function exerted by inhibiting muscle atrophy. The composition of the present invention may be labeled with at least one function selected from the group consisting of "inhibition of muscle loss," "muscle maintenance," "muscle improvement," "inhibition of muscle weakness," "muscle strength maintenance," "muscle strength improvement," "improvement of walking function," "maintenance of walking function," "improvement of motor function," "maintenance of motor function," "maintenance of muscle weakened by aging," "maintenance of muscle strength weakened by aging," and "maintenance of physical strength." In one aspect, the composition of the present invention is preferably a food or beverage labeled with the above-mentioned label. The above-mentioned label may also be a label indicating that the composition is used to achieve the above-mentioned function. The above-mentioned label may be attached to the composition itself, or to the container or packaging of the composition.
[0034] As described above, ergothioneine or a salt thereof has an Src tyrosine kinase inhibitory activity. Ergothioneine or a salt thereof can be used as an active ingredient for inhibiting Src tyrosine kinase. The composition of the present invention can also be used as a composition for inhibiting Src tyrosine kinase. A composition for inhibiting Src tyrosine kinase containing ergothioneine or a salt thereof as an active ingredient also constitutes the present invention. The active ingredient, content and dosage of the active ingredient, administration target, and other aspects of the composition for inhibiting Src tyrosine kinase are the same as those of the above-mentioned composition for inhibiting muscle atrophy.
[0035] As described above, ergothioneine or a salt thereof inhibits substrate binding to a K ATP channel. Therefore, ergothioneine or a salt thereof can also be used as an active ingredient for inhibiting substrate binding to a K ATP channel. A composition for inhibiting substrate binding to a K ATP channel, which contains ergothioneine or a salt thereof as an active ingredient, also constitutes one aspect of the present invention.
[0036] The present invention also encompasses the following methods: A method for inhibiting muscle atrophy, which comprises administering ergothioneine or a salt thereof to a subject; A method for inhibiting Src tyrosine kinase, which comprises administering ergothioneine or a salt thereof to a subject. The above methods may be therapeutic or non-therapeutic.
[0037] The present invention also encompasses the following uses: Use of ergothioneine or a salt thereof for suppressing muscle atrophy. Use of ergothioneine or a salt thereof for inhibiting Src tyrosine kinase. The above uses may be therapeutic or non-therapeutic. By administering ergothioneine or a salt thereof to a subject, muscle atrophy can be suppressed.
[0038] In the above-mentioned methods and uses, the preferred embodiment of ergothioneine or a salt thereof is the same as that of the composition of the present invention described above. As ergothioneine or a salt thereof, one type of ergothioneine or a salt thereof may be used, or two or more types may be used. In the above-mentioned methods and uses, it is preferable to administer (ingest) ergothioneine or a salt thereof to a subject at least once a day, for example, once to several times (e.g., two to three times) a day. In the above-mentioned methods and uses, it is preferable to orally administer (ingest) ergothioneine or a salt thereof. The above-mentioned uses are preferably used in humans or non-human mammals, more preferably in humans.
[0039] In the above-mentioned methods and uses, ergothioneine or a salt thereof may be used in an amount sufficient to achieve the desired effect (which may also be referred to as an effective amount). The preferred dosage and administration targets of ergothioneine or a salt thereof are the same as those of the above-mentioned composition of the present invention. Ergothioneine or a salt thereof may be administered directly or as a composition containing it. For example, the above-mentioned composition of the present invention may be used.
[0040] The present invention also encompasses the use of ergothioneine or a salt thereof for the manufacture of a composition for inhibiting muscle atrophy.The present invention also encompasses the use of ergothioneine or a salt thereof for the manufacture of a composition for inhibiting Src tyrosine kinase.The present invention also encompasses ergothioneine or a salt thereof for use in inhibiting muscle atrophy.
[0041] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.
[0042] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited to these examples.
[0043] Example 1 (Evaluation of muscle atrophy in humans) For the purpose of evaluating the effect of an ergothioneine-containing supplement on lean body mass in humans, a placebo-controlled, randomized, double-blind, parallel-group comparative study was conducted in healthy men and women aged 50 to 55 (12 in the test food group, 11 in the control food group, a total of 23 people) in which they took a capsule containing 8 mg of ergothioneine (test food) or a capsule not containing ergothioneine (control food) once a day for 12 weeks.
[0044] The lean percentage was evaluated using a DC-430A separate type body composition analyzer (manufactured by Tanita Corporation). First, the subjects' lean percentage was evaluated using the body composition analyzer before the start of the study (before starting to take the test food or control food). In addition, the subjects' lean percentage was measured again after 12 weeks of taking the test food or control food (12-week test).
[0045] (Foods for evaluation) Two types of foods were used for evaluation, which were indistinguishable in appearance, flavor, etc. Test food: Capsules containing the test substance (8 mg of L-ergothioneine) Control food: Capsules not containing the test substance In addition to the test substance, the ingredients of each food for evaluation include dextrin, calcium stearate, and hydroxypropyl methylcellulose. The control food was manufactured using the same ingredients as the test foods, except that it did not contain the test substance (L-ergothioneine).
[0046] The average value of the lean percentage (%) of the subjects in the test food group was taken as the lean percentage of the test food group. The average value of the lean percentage (%) of the subjects in the control food group was taken as the lean percentage of the control food group. In addition, for each group, the change in lean percentage (Δ lean percentage (%)) was calculated by subtracting the lean percentage at the pre-study test from the lean percentage at the 12-week test. The change in lean percentage (Δ lean percentage (%)) at the pre-study test was set to 0.
[0047] Figure 1 is a graph showing the change in lean mass (Δ lean mass (%)) in the test food group and the control food group. As a result, the decrease in lean mass was more suppressed in the test food group than in the control food group. These results demonstrate that L-ergothioneine suppresses muscle atrophy. In Figure 1, black squares (■) represent the test food group, and white squares (□) represent the control food group. "0W" on the horizontal axis represents the time of the test before the start of the study, and "12W" represents the time of the test at 12 weeks.
[0048] Example 2 (Evaluation of Src tyrosine kinase inhibitory activity) To evaluate the molecular target by which L-ergothioneine maintains lean mass, an in vitro assay for Src tyrosine kinase was carried out. The in vitro assay was conducted as a contract test at Eurofins Panlabs. The test was carried out by the following method.
[0049] Human recombinant Src tyrosine kinase expressed in insect cells was used. 0.023 μg / mL Src tyrosine kinase was preincubated with L-ergothioneine (L-ergothioneine concentrations: 10 μM and 1000 μM) in HEPES buffer (pH 7.4) at 37°C for 15 minutes. Furthermore, 0.2 mg / mL poly(Glu:Tyr), 10 μM ATP, 0.25 μM Ci[γ 32 The reaction was initiated by the addition of [P]ATP, and after a 30-minute incubation, the reaction was incubated with 3% H 3 P.O. 4 The reaction was stopped by adding 32 The inhibitory activity of L-ergothioneine was evaluated using the amount of [P]Poly(Glu:Tyr) formed as an index. 32The lower the amount of [P]Poly(Glu:Tyr), the more the activity of Src tyrosine kinase is inhibited.
[0050] 2 is a graph evaluating the inhibitory activity of L-ergothioneine against Src tyrosine kinase. The concentration (μM) on the horizontal axis is the concentration of L-ergothioneine. The percentage (%) of inhibitory activity against Src tyrosine kinase was calculated by the following procedure. 32 The amount of [P]Poly(Glu:Tyr) in the reaction mixture to which L-ergothioneine was added was set as 100% Src tyrosine kinase activity. 32 The relative activity (%) of Src tyrosine kinase relative to the control was calculated from the amount (%) of [P]Poly(Glu:Tyr). The inhibitory activity (%) of Src tyrosine kinase was calculated by subtracting the relative activity (%) of Src tyrosine kinase when L-ergothioneine was added from the Src tyrosine kinase activity of the control (100%). L-ergothioneine exhibited inhibitory activity against Src tyrosine kinase. Src tyrosine kinase is expressed in muscle, and its inhibition is known to suppress muscle cell degradation. Therefore, it is presumed that L-ergothioneine inhibits muscle cell degradation by inhibiting Src tyrosine kinase, thereby exhibiting the above-mentioned muscle atrophy inhibitory effect.
[0051] Example 3 (Evaluation of substrate binding inhibitory activity of ATP-sensitive potassium channels) To evaluate the molecular target of L-ergothioneine in maintaining lean mass, an in vitro assay for ATP-sensitive potassium channels was carried out. The in vitro assay was conducted by Eurofins Panlabs. The test was carried out by the following method.
[0052] 400 μg of membrane fraction from rat cerebral cortex (containing K ATP channels; Eurofins Cerep) was diluted with 0.1 nM [ 3The cells were incubated with [H] glibenclamide and L-ergothioneine (L-ergothioneine concentration: 100 μM or 1000 μM) at 22°C for 60 minutes. Glibenclamide is a K ATP channel inhibitor. Nonspecific binding was determined in the presence of 1 μM glibenclamide (no L-ergothioneine). When glibenclamide was present in excess, [ 3 Since [H]glibenclamide is no longer able to bind to the K ATP channel, the radioactivity detected there is nonspecific binding. The membrane fraction was filtered and washed, and the substrate binding inhibitory activity of L-ergothioneine was evaluated using radioactivity as an indicator. [H]glibenclamide bound to the K ATP channel 3 The higher the amount of [H]glibenclamide, the stronger the radioactivity of the membrane fraction.
[0053] FIG. 3 is a graph evaluating the substrate binding inhibitory activity of L-ergothioneine on ATP-sensitive potassium channels. The concentration (μM) on the horizontal axis represents the concentration of L-ergothioneine. The substrate binding inhibitory activity (%) on K ATP channels was determined by the following procedure. The radioactivity of the membrane fraction in the reaction solution without L-ergothioneine (control) was set to 100%, and the relative activity (%) of the membrane fraction in the reaction solution containing L-ergothioneine (100 μM or 1000 μM) relative to the control was calculated from the radioactivity of the membrane fraction. When L-ergothioneine inhibits the binding of glibenclamide to K ATP channels, the radioactivity of the membrane fraction is weakened. The substrate binding inhibitory activity (%) on K ATP channels was then calculated by subtracting the relative activity (%) of the membrane fraction in the control (100%).
[0054] L-ergothioneine exhibited inhibitory activity against the binding of its substrate, glivenclamide, to ATP-sensitive potassium channels. ATP-sensitive potassium channels are also expressed in muscles and are known to be involved in regulating the muscle atrophy process. Therefore, it is presumed that L-ergothioneine exerted the above-mentioned muscle atrophy inhibitory effect via ATP-sensitive potassium channels.
Claims
1. A composition for inhibiting muscle atrophy, comprising ergothioneine or a salt thereof as an active ingredient.
2. The composition according to claim 1, wherein the muscle atrophy is age-related muscle atrophy.
3. The composition described in claim 1 or 2, which inhibits muscle atrophy via ATP-sensitive potassium channels.
4. A composition for inhibiting Src tyrosine kinase, comprising ergothioneine or a salt thereof as an active ingredient.
5. The composition according to claim 1 or 4, which is an oral composition.
6. The composition according to claim 5, which is a food or drink.
7. The composition according to claim 1 or 4, which is labeled with at least one function selected from the group consisting of "inhibition of muscle loss," "muscle maintenance," "muscle improvement," "inhibition of muscle weakness," "muscle strength maintenance," "muscle strength improvement," "improvement of walking function," "maintenance of walking function," "improvement of motor function," "maintenance of motor function," "maintenance of muscle weakened by aging," "maintenance of muscle strength weakened by aging," and "maintenance of physical strength." 8. A method for inhibiting muscle atrophy, comprising administering ergothioneine or a salt thereof to a subject.
9. A method for inhibiting Src tyrosine kinase, comprising administering ergothioneine or a salt thereof to a subject.
10. Use of ergothioneine or a salt thereof for inhibiting muscle atrophy.
11. Use of ergothioneine or a salt thereof for inhibiting Src tyrosine kinase.
